This is why we emphasize that weight loss is not a one-size-fits-all solution
In contrast to these results, a study using nationwide registry data from Sweden, Denmark, and Norwayinvolving 121,254 new GLP-1 RA users and 185,027 new SGLT-2 inhibitor users documented 557 intestinal obstruction events, with no significant correlation between GLP-1 RA use and increased intestinal obstruction risk, thereby refuting earlier safety concerns [12]
doi:10.1177/0748233709348393 Islam, M.T., Mishra, S.K., Tripathi, S., de Alencar, M.V.O.B., e Sousa, J.M.d.C., Rolim, H.M.L., de Medeiros, M.d.G.F., Ferreira, P.M.P., Rouf, R., Uddin, S.J., Mubarak, M.S
And you improve your metabolic health